FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806104583> ?p ?o ?g. }

• W2806104583 endingPage "68" @default.
• W2806104583 startingPage "56" @default.
• W2806104583 abstract "Inducing DNA damage is known to be one of the mechanisms of cytotoxic chemotherapy agents for cancer such as cisplatin. The endogenous DNA damage response confers chemoresistance to these agents by repairing DNA damage. The initiation and transduction of the DNA damage response (DDR) signaling pathway, which is dependent on the activation of ATM (ataxia-telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related), is essential for DNA damage repair, the maintenance of genomic stability and cell survival. Therefore, ATM or ATR inhibition is considered as a promising strategy for sensitizing cancer cells to chemotherapy. This study is aimed to explore the effect of ATR inhibitor on sensitizing ESCC (esophageal squamous cell carcinoma) cells to cisplatin, and whether ATM deficiency could impact the sensitization. We found that 21.5% of ESCC cases had ATM deficiency and that patients with ATR activation after neoadjuvant chemotherapy had worse chemotherapy response and poorer overall survival than that without ATR activation (32 mons vs. >140mons). Then, it was shown that VE-822 inhibited ATR-CHK1 pathway activation, leading to the accumulation of cisplatin-modified DNA. And it inhibited cell proliferation, induced cell cycle arrest in G1 phase and enhanced cell apoptosis. Moreover, VE-822 significantly sensitized ESCC cells to cisplatin, and these two drugs had synergistic effects, especially in ATM-deficient cells, in vitro and in vivo. Our results suggest that ATR inhibition combining with cisplatin is a new strategy for managing patients with ESCC, especially those with ATM-deficiency. However, this is an idea that requires further validation." @default.
• W2806104583 created "2018-06-13" @default.
• W2806104583 creator A5000005088 @default.
• W2806104583 creator A5016611595 @default.
• W2806104583 creator A5026379419 @default.
• W2806104583 creator A5032402479 @default.
• W2806104583 creator A5041941283 @default.
• W2806104583 creator A5050540557 @default.
• W2806104583 creator A5059509650 @default.
• W2806104583 creator A5062852782 @default.
• W2806104583 creator A5073121428 @default.
• W2806104583 creator A5079768593 @default.
• W2806104583 creator A5083242381 @default.
• W2806104583 date "2018-09-01" @default.
• W2806104583 modified "2023-10-15" @default.
• W2806104583 title "The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma" @default.
• W2806104583 cites W1516887093 @default.
• W2806104583 cites W1757407923 @default.
• W2806104583 cites W1989475021 @default.
• W2806104583 cites W2010934271 @default.
• W2806104583 cites W2022529631 @default.
• W2806104583 cites W2054305985 @default.
• W2806104583 cites W2059128931 @default.
• W2806104583 cites W2061197983 @default.
• W2806104583 cites W2096439168 @default.
• W2806104583 cites W2097027018 @default.
• W2806104583 cites W2113704699 @default.
• W2806104583 cites W2122352172 @default.
• W2806104583 cites W2133106304 @default.
• W2806104583 cites W2141037581 @default.
• W2806104583 cites W2161395451 @default.
• W2806104583 cites W2177777322 @default.
• W2806104583 cites W2266880603 @default.
• W2806104583 cites W2272984102 @default.
• W2806104583 cites W2414367793 @default.
• W2806104583 cites W2502508548 @default.
• W2806104583 cites W2580220347 @default.
• W2806104583 cites W2597695339 @default.
• W2806104583 cites W2605017029 @default.
• W2806104583 cites W2677474623 @default.
• W2806104583 cites W2752541818 @default.
• W2806104583 cites W2762865482 @default.
• W2806104583 cites W2781501555 @default.
• W2806104583 cites W2789387026 @default.
• W2806104583 cites W2794941912 @default.
• W2806104583 cites W2796821211 @default.
• W2806104583 cites W2801282015 @default.
• W2806104583 cites W2802959410 @default.
• W2806104583 doi "https://doi.org/10.1016/j.canlet.2018.06.010" @default.
• W2806104583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29890208" @default.
• W2806104583 hasPublicationYear "2018" @default.
• W2806104583 type Work @default.
• W2806104583 sameAs 2806104583 @default.
• W2806104583 citedByCount "37" @default.
• W2806104583 countsByYear W28061045832018 @default.
• W2806104583 countsByYear W28061045832019 @default.
• W2806104583 countsByYear W28061045832020 @default.
• W2806104583 countsByYear W28061045832021 @default.
• W2806104583 countsByYear W28061045832022 @default.
• W2806104583 countsByYear W28061045832023 @default.
• W2806104583 crossrefType "journal-article" @default.
• W2806104583 hasAuthorship W2806104583A5000005088 @default.
• W2806104583 hasAuthorship W2806104583A5016611595 @default.
• W2806104583 hasAuthorship W2806104583A5026379419 @default.
• W2806104583 hasAuthorship W2806104583A5032402479 @default.
• W2806104583 hasAuthorship W2806104583A5041941283 @default.
• W2806104583 hasAuthorship W2806104583A5050540557 @default.
• W2806104583 hasAuthorship W2806104583A5059509650 @default.
• W2806104583 hasAuthorship W2806104583A5062852782 @default.
• W2806104583 hasAuthorship W2806104583A5073121428 @default.
• W2806104583 hasAuthorship W2806104583A5079768593 @default.
• W2806104583 hasAuthorship W2806104583A5083242381 @default.
• W2806104583 hasConcept C105696609 @default.
• W2806104583 hasConcept C134935766 @default.
• W2806104583 hasConcept C143425029 @default.
• W2806104583 hasConcept C190283241 @default.
• W2806104583 hasConcept C2776694085 @default.
• W2806104583 hasConcept C2778239845 @default.
• W2806104583 hasConcept C2779486608 @default.
• W2806104583 hasConcept C29537977 @default.
• W2806104583 hasConcept C50001416 @default.
• W2806104583 hasConcept C502942594 @default.
• W2806104583 hasConcept C54355233 @default.
• W2806104583 hasConcept C552990157 @default.
• W2806104583 hasConcept C55493867 @default.
• W2806104583 hasConcept C86803240 @default.
• W2806104583 hasConceptScore W2806104583C105696609 @default.
• W2806104583 hasConceptScore W2806104583C134935766 @default.
• W2806104583 hasConceptScore W2806104583C143425029 @default.
• W2806104583 hasConceptScore W2806104583C190283241 @default.
• W2806104583 hasConceptScore W2806104583C2776694085 @default.
• W2806104583 hasConceptScore W2806104583C2778239845 @default.
• W2806104583 hasConceptScore W2806104583C2779486608 @default.
• W2806104583 hasConceptScore W2806104583C29537977 @default.
• W2806104583 hasConceptScore W2806104583C50001416 @default.
• W2806104583 hasConceptScore W2806104583C502942594 @default.
• W2806104583 hasConceptScore W2806104583C54355233 @default.
• W2806104583 hasConceptScore W2806104583C552990157 @default.

• next